ConductScience.org, home

Paper385138

Etoposide (VP-16-213).

Issell BF and 1 other. Cancer Treat Rev, 1979. Cited by 170 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Etoposide (VP-16-213). Papers, record 385138. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/385138

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Etoposide (VP-16-213).
PubMed
Journal
Cancer Treat Rev
PubMed
Year
1979
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
170
iCite
Relative citation ratio, by iCite
7.4
iCite
Revised in PubMed
2019-10-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Issell BFB F
2Crooke STS T

Source PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EtoposideMajor topic
NeoplasmsMajor topic
PodophyllotoxinMajor topic
Adult
Animals
Bone Marrow
Cell Cycle
Child
Digestive System
Drug Therapy, Combination
Female
Humans
Leukemia
Lung Neoplasms
Lymphoma
Male
Mice
Neoplasms, Experimental
Rats

Source PubMed

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.

PMIDTitleJournalYearIn PapersSource
41,766,523A Critical Analysis of the Impact of Etoposide as a Topoisomerase II Inhibitor in Cervical Cancer Treatment: A Review.Cancer Med2026https://conductscience.org/library/papers/41766523PubMed
41,384,121Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review.Front Med (Lausanne)2025https://conductscience.org/library/papers/41384121PubMed
39,981,182A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors.Front Pharmacol2025https://conductscience.org/library/papers/39981182PubMed
21,822,607A new iridoid glycoside and NO production inhibitory activity of compounds isolated from Russelia equisetiformis.J Nat Med2012https://conductscience.org/library/papers/21822607PubMed
21,240,679Constituents of cultivated Agaricus blazei.J Nat Med2011https://conductscience.org/library/papers/21240679PubMed
18,409,065Rearranged ent-kauranes from the stems of Tricalysia dubia and their biological activities.J Nat Med2008https://conductscience.org/library/papers/18409065PubMed
10,711,848Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies.Drugs1999https://conductscience.org/library/papers/10711848PubMed
8,690,756Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer.J Cancer Res Clin Oncol1996https://conductscience.org/library/papers/8690756PubMed
7,781,140Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis.Cancer Chemother Pharmacol1995https://conductscience.org/library/papers/7781140PubMed
7,083,463Phase II study of VP16-213 (etoposide) in refractory metastatic breast carcinoma.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083463PubMed
7,083,454Pharmacokinetics of VP16-213 given by different administration methods.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083454PubMed
7,083,453Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083453PubMed
7,083,452Interaction of VP16-213 with the DNA repair antagonist chloroquine.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083452PubMed
7,083,450Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7083450PubMed
7,044,596Current development of podophyllotoxins.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044596PubMed
7,044,594VP16-213 (etoposide). A critical review of its activity.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044594PubMed
7,044,593The podophyllotoxin derivatives VP16-213 and VM26.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044593PubMed
7,044,592The clinical pharmacology of VM26 and VP16-213. A brief overview.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044592PubMed
7,044,591VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044591PubMed
7,031,350[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].Klin Wochenschr1981https://conductscience.org/library/papers/7031350PubMed

See all 38 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/385138

GET https://conductscience.org/api/papers/v1/385138/cited_by?page=2